S Peter Kang - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

S Peter Kang

Showing results (21-30 of 24) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 24 results.

JAMA|April 20, 2016

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaAntoni Ribas, Omid Hamid, Adil Daud, et al.

Cancer Immunology Research|October 18, 2017

A Blueprint to Advance Colorectal Cancer ImmunotherapiesDung T Le, Vanessa M Hubbard-Lucey, Michael A Morse, et al.

The Lancet. Oncology|June 28, 2015

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.

Science (New York, N.Y.)|June 10, 2017

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T Le, Jennifer N Durham, Kellie N Smith, et al.

Pageof 3

Search research articles

Showing results (21-30 of 24) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 24 results.

JAMA|April 20, 2016

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaAntoni Ribas, Omid Hamid, Adil Daud, et al.

Cancer Immunology Research|October 18, 2017

A Blueprint to Advance Colorectal Cancer ImmunotherapiesDung T Le, Vanessa M Hubbard-Lucey, Michael A Morse, et al.

The Lancet. Oncology|June 28, 2015

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.

Science (New York, N.Y.)|June 10, 2017

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T Le, Jennifer N Durham, Kellie N Smith, et al.

Pageof 3